N/A N=174 Diagnostic

TOF-18F-FDG-PET/CT in Patients With Suspected Pancreatic Cancer

Pancreatic Cancer · Pancreatitis · IPMN

Bottom Line

View on ClinicalTrials.gov: NCT03914950 ↗

Enrolled (actual)

174

Serious AEs

0.0%

Results posted

May 2020

Primary outcome: Primary: SUVmax (Maximal Standard Uptake Value) Measurement 30 and 90 Min p.i. (Post Injection) — 0.77; 0.78; 0.81; 0.8 SUVmax — p=0.78

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: PET/CT results with TOF/without TOF (Diagnostic_test)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: Medical University of Graz
Primary completion: Jan 2019

Outcome Measures

Outcome	Result	p-value
PRIMARY SUVmax (Maximal Standard Uptake Value) Measurement 30 and 90 Min p.i. (Post Injection)	0.77; 0.78; 0.81; 0.8	0.78
PRIMARY Participants With Increased Tracer Uptake Over the Pancreatic Lesion With and Without TOF	116; 101	—
SECONDARY Lesion Size	3.0	—

Summary

Aim of the prospective study is a better differentiation of benign and malignant lesions in the pancreas in patients with suspected pancreatic cancer using images 30 and 90 min p.i. (post injectionen) and a diagnostic CT (computed tomography) scan of the abdomen within the Time of Flight (TOF)-18F-FDG-PET/CT and thus an improvement of the quality of PET/CT findings.

Eligibility Criteria

Inclusion Criteria

patients with suspected pancreatic cancer

Exclusion Criteria

persons under 18 years of age
patients with blood glucose level ≥160 mg/dl at the time of the PET/CT examination
patients who will not be operated or biopsied and in which thus there are no histopathological findings of the pancreas
pregnant women

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03914950). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.